Eventide Asset Management LLC Makes New $7.33 Million Investment in Encompass Health Corporation $EHC

Eventide Asset Management LLC purchased a new position in shares of Encompass Health Corporation (NYSE:EHC) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 68,968 shares of the company’s stock, valued at approximately $7,330,000.

Other large investors also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. increased its position in shares of Encompass Health by 3,059,159.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock worth $402,640,000 after acquiring an additional 3,793,358 shares in the last quarter. AlphaCore Capital LLC acquired a new stake in shares of Encompass Health in the fourth quarter worth $4,881,000. Tudor Investment Corp ET AL increased its position in shares of Encompass Health by 155.3% in the third quarter. Tudor Investment Corp ET AL now owns 210,712 shares of the company’s stock worth $26,765,000 after acquiring an additional 128,191 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Encompass Health by 5.3% in the third quarter. JPMorgan Chase & Co. now owns 1,410,335 shares of the company’s stock worth $179,141,000 after acquiring an additional 70,387 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Encompass Health by 1,070.9% in the fourth quarter. SG Americas Securities LLC now owns 88,054 shares of the company’s stock worth $9,346,000 after acquiring an additional 80,534 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Insider Buying and Selling

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $104.56, for a total transaction of $71,309.92. Following the transaction, the executive vice president directly owned 24,755 shares in the company, valued at $2,588,382.80. This represents a 2.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.80% of the stock is owned by company insiders.

Encompass Health Trading Up 0.0%

NYSE EHC opened at $101.49 on Monday. Encompass Health Corporation has a 12 month low of $92.77 and a 12 month high of $127.99. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.17 and a quick ratio of 1.17. The company has a market capitalization of $10.07 billion, a price-to-earnings ratio of 16.94, a price-to-earnings-growth ratio of 2.21 and a beta of 0.72. The company’s fifty day moving average price is $104.31 and its two-hundred day moving average price is $104.59.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Thursday, April 30th. The company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.51 by $0.09. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the prior year, the firm posted $1.37 EPS. The firm’s revenue was up 9.0% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. As a group, research analysts predict that Encompass Health Corporation will post 5.97 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Wednesday, July 1st will be paid a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, July 1st. Encompass Health’s dividend payout ratio is 12.69%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. TD Cowen assumed coverage on shares of Encompass Health in a research report on Thursday, May 28th. They issued a “buy” rating and a $125.00 price objective for the company. Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Barclays dropped their price objective on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research report on Tuesday, May 5th. Leerink Partners set a $152.00 price target on shares of Encompass Health in a report on Friday, May 22nd. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Encompass Health in a report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Encompass Health has a consensus rating of “Buy” and a consensus target price of $143.86.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post?acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end?of?life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.